Phase 3 Treatment Clinical Trials
16 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–16 of 16 trials
Recruiting
Phase 2Phase 3
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
TreatmentSurvivalClassical Hodgkin Lymphoma+6 more
Children's Cancer Group, China96 enrolled1 locationNCT06563245
Recruiting
Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
Major Depressive DisorderTreatment Resistant Depression
Weill Medical College of Cornell University348 enrolled2 locationsNCT04041479
Recruiting
Phase 3
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA400 enrolled5 locationsNCT07184619
Recruiting
Phase 3
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.662 enrolled1 locationNCT07238283
Recruiting
Phase 3
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Major Depressive DisorderTreatment Resistant Depression
Dr. Inge Winter418 enrolled12 locationsNCT05973851
Recruiting
Phase 3
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
Treatment Resistant DepressionRefractory Depression
University of North Carolina, Chapel Hill23 enrolled1 locationNCT06303739
Recruiting
Phase 3
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Major Depressive DisorderTreatment Resistant Depression
Università Vita-Salute San Raffaele30 enrolled1 locationNCT07088380
Recruiting
Phase 3
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.880 enrolled1 locationNCT05838066
Recruiting
Phase 3
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
HIV InfectionsSubstance UseAdherence, Treatment+1 more
Brigham and Women's Hospital40 enrolled1 locationNCT05378399
Recruiting
Phase 2Phase 3
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting
Phase 3
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Urinary Bladder NeoplasmsTreatment OutcomeImmunotherapy, Active+3 more
Fujian Medical University Union Hospital76 enrolled1 locationNCT06441110
Recruiting
Phase 3
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
First-line Treatment of Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.778 enrolled1 locationNCT05751850
Recruiting
Phase 3
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University312 enrolled1 locationNCT06278870
Recruiting
Phase 3
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891
Recruiting
Phase 3
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Esophageal CancerSurgeryNeoadjuvant Treatment+1 more
Henan Cancer Hospital400 enrolled1 locationNCT04280822
Recruiting
Phase 3
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
ChemotherapyRadiotherapyNasopharyngeal Carcinoma+1 more
Sun Yat-sen University226 enrolled6 locationsNCT04453813